Drug class
Dual endothelin receptor antagonist (ERA); vasodilator for pulmonary arterial hypertension
Mechanism of action
Competitively antagonises endothelin ETA and ETB receptors. This reduces endothelin-mediated vasoconstriction and proliferative effects in pulmonary vascular smooth muscle, lowering pulmonary vascular resistance.
General use cases
- Treatment of pulmonary arterial hypertension (PAH) to improve exercise ability and reduce clinical worsening in eligible adults and paediatric patients; current age, functional-class and monitoring criteria are product-label specific
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
